Relpax (eletriptan) 40 mg dosage

Relpax tablets should be taken as early as possible after the onset of migraine headache but they are also effective if taken at a later stage during a migraine attack.

Relpax, if taken during the aura phase, has not been demonstrated to prevent migraine headache and therefore Relpax should only be taken during the headache phase of migraine.

Adults (18-65 years of age):

The recommended initial dose is 40mg.

If the migraine headache returns within 24 hours of an initial response, a second dose of the same strength of Relpax has been shown to be effective in treating the recurrence. If a second dose is required, it should not be taken within 2 hours of the initial dose.

If no response is obtained: If a patient does not achieve a headache response to the first dose of Relpax within 2 hours, a second dose should not be taken for the same attack as clinical trials have not adequately established efficacy with the second dose. Clinical trials show that patients who do not respond to the treatment of an attack are still likely to respond to the treatment of a subsequent attack.

Patients who do not obtain satisfactory efficacy after an appropriate trial of 40mg, (e.g. good tolerability and failure to respond in 2 out of 3 attacks), may be effectively treated with 80mg (2 x 40mg) in subsequent migraine attack. A second dose of 80mg should not be taken within 24 hours.

The maximum daily dose should not exceed 80mg.

Elderly (over 65 years of age)

The safety and effectiveness of eletriptan in patients over 65 years of age have not been systematically evaluated due to the small number of such patients in clinical trials. Use of Relpax in the elderly is therefore not recommended.

Adolescents (12-17 years of age) and Children (6-11 years of age)

The safety and efficacy of Relpax has not been established in this population and its use is therefore not recommended in this age group.

Hepatic Impairment

No dose adjustment is required in patients with mild or moderate hepatic impairment. As Relpax has not been studied in patients with severe hepatic impairment, it is contra-indicated in these patients.

Renal Impairment

As the blood pressure effects of Relpax are amplified in renal impairment, a 20mg initial dose, is recommended in patients with mild or moderate renal impairment. The maximum daily dose should not exceed 40mg. Relpax is contra-indicated, in patients with severe renal impairment.

For children under 17 years and elderly over 65 years of age, Relpax is not recommended.